Validation Expectations for AI-Generated Regulatory Content

Introduction

Since 2016, the FDA's Center for Drug Evaluation and Research has reviewed more than 500 drug and biological product submissions containing AI-generated or AI-supported components ^[1]. Those components span a broad range of AI use in drug development, from predictive modeling to data analysis; the figure reflects broad AI adoption in submissions, not document drafting specifically. Within that broader shift, sponsors and CROs have increasingly deployed large language models to draft clinical trial protocols, informed consent forms (ICFs), investigator brochures (IBs), development safety update reports (DSURs), and clinical study reports (CSRs). They are doing this within GxP frameworks originally built for deterministic software, not probabilistic language models. The gap between deployment speed and compliance infrastructure is visible to regulators, and the regulatory response has accelerated across multiple agencies.

Several major documents published in 2024, 2025, and 2026 have raised and clarified expectations: the EMA's final Reflection Paper on AI in the Medicinal Product Lifecycle (September 2024) ^[2], ICH E6(R3)'s Step 4 endorsement by the ICH Assembly (January 2025) ^[3], FDA's draft guidance proposing a risk-based credibility framework for AI supporting regulatory decision-making (January 2025) ^[4], and the joint FDA/EMA Guiding Principles of Good AI Practice in Drug Development (January 2026) ^[17]. Each of these documents approaches the problem from a different angle, with different scope and different levels of binding force. Reading them correctly, rather than conflating them, is one of the more consequential compliance tasks currently facing regulatory affairs teams.

This article works through what those frameworks mean operationally: which apply directly to AI document generation tools, which serve as authoritative best-practice analogues, what the validation package should contain, where conventional CSV falls short for AI systems, and where accountability rests.

Why This Topic Matters in Clinical Trials

The stakes of errors in regulatory documents are not equivalent to errors in a marketing brochure. A protocol defines what happens to trial participants. An ICF governs what those participants understood and consented to. A CSR forms the evidentiary basis on which a marketing authorization decision is made. When AI introduces factual errors, omissions, or fabricated content into any of these documents, the consequences can include protocol deviations, regulatory inspection findings, consent validity challenges, or compromised regulatory submissions.

Accuracy data for AI systems in clinical document contexts gives a concrete sense of the risk. A 2025 study published in npj Digital Medicine assessed LLM-based clinical text generation across 12,999 clinician-annotated sentences and found a 1.47% hallucination rate and a 3.45% omission rate ^[5]. In a 50-page protocol, even a 1.47% content error rate translates into multiple fabricated or missing details that a reviewer checking for readability would not independently detect. A separate 2025 preprint from the InformGen research group evaluated AI-generated informed consent documents against verified trial protocols and found that a general-purpose large language model achieved only 57% to 82% factual accuracy for ICF generation, rising above 90% only when structured human expert review was incorporated into the workflow ^[6]. A 2025 scoping review of LLMs in clinical documentation found frequent reports of factual errors, omissions, and hallucinations across diverse clinical scenarios ^[7].

The FDA's own operational experience adds a real-world reference point. The agency's internal AI assistant encountered hallucination problems during its initial deployment, including false citations and data errors; in response, the FDA stated publicly that its AI tools "do not make regulatory decisions or replace human judgment" and that human oversight remains essential throughout AI-supported workflows ^[8].

These are not isolated findings. They describe a class of failure that validation frameworks must explicitly address.

Which Regulatory Frameworks Apply, and How

Not all of the frameworks commonly cited in this area apply to AI document generation tools with equal directness, binding force, or scope. Treating guidance principles, industry frameworks, and regulations as interchangeable leads to both under- and over-compliance. The table below shows how each framework should be characterized and applied.

Framework Applicability at a Glance

Legend: B = Binding regulation or adopted guideline | E = Regulatory expectation (non-binding guidance, principles, or reflection paper) | G = Industry guidance or best practice

21 CFR Part 11 and ALCOA Data Integrity

FDA's regulation on electronic records and electronic signatures (21 CFR Part 11) has applied to GxP computerized systems since 1997 ^[9]. It is relevant to AI document generation tools where two conditions are met: the records or signatures being created are subject to FDA predicate-rule requirements (such as 21 CFR Part 312 for IND studies or 21 CFR Part 50 for informed consent documentation), and those records are created or maintained in electronic form ^[9]. When both conditions apply, Part 11's validation, audit trail, and electronic signature controls govern the system.

The ALCOA data integrity principles (Attributable, Legible, Contemporaneous, Original, Accurate) are articulated in FDA's data integrity guidance ^[10] and reinforced across ICH E6(R3) ^[3]. Part 11's specific requirements for audit trails, validation, and record security are designed to achieve these properties in electronic systems. In industry practice, an expanded set of properties (often termed ALCOA+, adding Complete, Consistent, Enduring, and Available) reflects expectations from WHO, MHRA, and other regulatory bodies, though these additional properties do not appear as a named framework in any single US regulatory document.

For AI document generation, these properties introduce specific operational demands. Attributability in an AI context means recording not just the human reviewer's identity but also the model version, prompt template, and input source that produced the AI output. Contemporaneousness means AI outputs and review decisions should be time-stamped at the moment of action. Originality creates an important question about the AI-generated draft: if the SOP, predicate rule requirements, and the organization's record management policy treat the draft as a controlled record, that draft should be retained in original form, with the progression to final approved text maintained as a traceable change history.

Whether an AI-generated draft constitutes a GxP record depends on the organization's SOPs, the applicable predicate rules, and how the draft enters the regulatory workflow. Organizations should resolve this classification in policy before deploying an AI document tool, because the answer determines which Part 11 controls apply to the generation workflow.

ICH E6(R3): GCP Computerized Systems Validation

ICH E6(R3) was endorsed at Step 4 by the ICH Assembly on January 6, 2025, and adopted by the EMA with effect from July 23, 2025 ^[3]. The guideline gives computerized systems validation considerably more structural attention than E6(R2) did, addressing system validation, user responsibilities, data governance, and operational controls in a dedicated chapter applicable to all systems supporting the conduct of a GCP clinical trial.

Two updates are particularly relevant to AI document generation tools. First, the guideline requires that data acquisition tools be validated before their required use in a trial ^[3]. Not every protocol or CSR drafting tool functions as a data acquisition tool in the E6(R3) sense. Organizations should assess whether their specific AI tool captures or processes source trial data, and apply the data acquisition tool requirements accordingly rather than assuming automatic coverage.

Second, the guideline introduces a lifecycle expectation: periodic review may be needed to confirm that computerized systems remain in a validated state across their operational lifespan ^[3]. This directly addresses the AI-specific challenge of performance change over time. A model updated by the provider without sponsor initiation, a revised prompt template, or a shift in the types of source documents the tool receives are all potential state changes that warrant assessment.

ICH E6(R3) also addresses data governance explicitly, requiring audit trail controls, user authentication, and cybersecurity measures for all systems handling clinical trial records ^[3]. For AI document generation platforms connected to source data systems such as CTMS or eCTD repositories, the interface between systems falls within this scope.

FDA Draft Guidance on AI Supporting Regulatory Decision-Making

Published January 6, 2025, FDA's draft guidance "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" ^[4] proposes a seven-step risk-based credibility assessment framework: define the question of interest; define the Context of Use (COU); assess the model's risk; develop a credibility assessment plan proportionate to that risk; execute the plan; document results and deviations; determine whether the model is adequate for the defined COU.

The guidance contains an explicit scope exclusion. It does not apply to AI used to simplify operations, such as drafting a regulatory submission, when that use does not directly affect patient safety, drug quality, or the reliability of nonclinical or clinical study results ^[4]. An AI tool that drafts a CSR from sponsor-supplied verified data, where the AI contributes narrative rather than analytical outputs informing regulatory decisions, may fall outside this guidance's direct scope.

For organizations whose AI document workflows involve records and signatures subject to GxP predicate rules, those validation and data integrity obligations exist independently of this guidance and apply whether or not the credibility framework is in scope. The seven-step credibility framework represents the outer ceiling for AI systems that directly inform regulatory decisions; GxP validation expectations represent the baseline for any computerized system operating in a regulated clinical context.

EMA Reflection Paper on AI in the Medicinal Product Lifecycle

The EMA's Reflection Paper on AI in the Medicinal Product Lifecycle reached its final form on September 9, 2024 ^[2]. It establishes two internal risk categories: AI systems with "high patient risk" directly affect participant safety, and those with "high regulatory impact" substantially influence regulatory decision-making. These are EMA-specific categories for calibrating oversight within the medicinal product lifecycle. They are distinct from the EU AI Act's classification scheme, which uses different criteria and is discussed separately below.

A protocol generation tool that informs participant eligibility criteria or dosing logic may attract both categories. A CSR drafting tool that compiles narrative from pre-analyzed data may not, depending on what inputs it processes and what decisions flow from its outputs. The EMA does not provide a bright-line rule; organizations should assess each tool against its specific function.

The Reflection Paper explicitly names clinical trial sponsors, alongside marketing authorization holders and manufacturers, as responsible parties for ensuring AI tools in their workflows are fit for purpose and aligned with applicable standards ^[2]. A vendor's validation documentation provides useful supplementary evidence, but it does not transfer sponsor accountability. The sponsor remains responsible for fitness-for-purpose regardless of who built the tool.

The Reflection Paper also calls for lifecycle governance, traceability of AI outputs to source data, and a human-centric approach across all phases of AI use ^[2].

FDA/EMA Good AI Practice Principles for Drug Development

On January 14, 2026, the FDA and EMA jointly published the Guiding Principles of Good AI Practice in Drug Development ^[17]. The 10 principles are not legally binding and do not constitute formal regulatory guidance, but they represent the first jointly issued AI framework from both agencies and signal where future guidance from each is likely to converge.

The principles cover: human-centric design; alignment with ethical values; adherence to relevant drug development standards; a risk-based approach; context of use; rigorous data governance; multidisciplinary expertise; lifecycle management; transparency and communication about AI systems; and human oversight. Several of these directly address questions that validation programs for AI document generation tools must resolve. Lifecycle management, for example, reinforces the ICH E6(R3) expectation of periodic review rather than one-time certification. Context of use as a framing principle aligns with the credibility framework's COU concept. The transparency principle supports the case for source-grounded architectures that make AI outputs auditable.

These principles are intended to inform future regulatory policies and guidance in both jurisdictions, and organizations building AI validation programs now should design them against these principles alongside the frameworks already in force.

Good Machine Learning Practice and GAMP 5

In October 2021, the FDA, Health Canada, and the UK's MHRA jointly published ten Good Machine Learning Practice (GMLP) guiding principles for AI/ML-based systems ^[11]. These were developed for the medical device context but their requirements for data quality, test set independence, explainability, and human-AI team performance are instructive across any GxP application of AI. The January 2026 FDA/EMA Good AI Practice principles extend and build on the GMLP work into the drug development context, providing the most current joint regulatory reference for lifecycle-aware AI governance in drug development ^[17].

The ISPE GAMP 5 Second Edition (2022), specifically Appendix D11, extends the traditional computerized system lifecycle to AI/ML applications by incorporating training, validation, and test data splitting, iterative fine-tuning, and ongoing performance monitoring within a risk-based framework ^[12]. The ISPE GAMP Guide: Artificial Intelligence (July 2025) provides more detailed guidance on explainability requirements, hallucination risk controls, bias detection, and data governance specific to large language models in GxP contexts ^[13]. Both are industry guidance rather than regulatory requirements; they represent the most operationally detailed frameworks currently available for AI validation program design.

The EU AI Act: A Separate Classification Exercise

Note: The EU AI Act implementation schedule is subject to ongoing legislative developments. The dates below reflect the provisional political agreement on the Digital Omnibus on AI reached May 7, 2026 by the Council of the EU and the European Parliament ^[18]. Formal adoption and publication in the Official Journal had not occurred as of this article's publication. Organizations should verify current dates against European Commission publications before making compliance planning decisions.

The EU AI Act (Regulation 2024/1689) entered into force on August 1, 2024 ^[14]. Obligations for general-purpose AI model providers took effect August 2, 2025. Following the Digital Omnibus political agreement of May 7, 2026, high-risk system obligations have been extended: stand-alone high-risk AI systems under Annex III are now expected to comply by December 2, 2027, and AI systems embedded in regulated products under Annex I (including medical devices subject to third-party conformity assessment) by August 2, 2028 ^[18]. These dates are the operative planning baseline and remain pending formal adoption and publication of the Omnibus in the Official Journal ^[18].

A fundamental clarification: "high regulatory impact" under the EMA's Reflection Paper is not the same classification as "high-risk AI system" under the EU AI Act. The two frameworks use different terminology, different criteria, and serve different regulatory purposes.

The EU AI Act's Annex III defines specific categories of high-risk AI systems covering areas including biometric identification, critical infrastructure management, employment decisions, law enforcement, migration control, and the administration of justice. An AI system qualifies as high-risk under Article 6(1) only if it is a safety component of a product subject to listed EU harmonization legislation (such as medical devices under MDR or IVDR) requiring third-party conformity assessment. A document drafting tool for clinical trials is generally not a medical device, nor a safety component of one. It does not automatically qualify as a high-risk system under Annex III or Article 6 of the EU AI Act.

Sponsors should conduct a formal classification assessment for each AI tool deployed in their workflows, rather than assuming either high-risk status or categorical exemption. That assessment should consider the tool's specific function, its relationship to any regulated products, and whether GPAI obligations apply where a foundation model is being deployed. The EMA Reflection Paper and EU AI Act operate in parallel and must both be addressed; they overlap in some areas but neither framework substitutes for the other.

Operational Considerations for AI Document Validation

The following section describes controls and documentation approaches that reflect a combination of regulatory obligations, regulatory expectations, and industry best practice. Organizations should assess each control against the specific regulations and guidelines applicable to their workflows before categorizing it as a legal requirement or a prudent compliance investment. Where a control is derived from a binding regulation (such as 21 CFR Part 11 or ICH E6(R3)), the underlying obligation should be cited in the organization's validation documentation. Where it reflects guidance or best practice, it should be framed accordingly.

Why AI Validation Differs from Conventional CSV

Traditional computerized system validation rests on one foundational premise: a validated system, given the same inputs, produces the same outputs every time. That premise does not hold for generative AI. The same prompt may yield different text across runs. Model behavior may change following a provider-initiated update. Performance may degrade as the distribution of input documents shifts over months of production use.

FDA's Computer Software Assurance guidance (finalized September 24, 2025) was developed specifically for device production and quality system software ^[15]. Its risk-based, outcome-focused framing, where assurance effort is proportionate to risk rather than driven by documentation volume, illustrates a direction that also informs how risk-based validation programs for AI document tools are designed, even though the guidance itself is not directly applicable to clinical document generation.

A risk management approach aligned with ICH Q9(R1) principles provides a useful analytical framework for identifying and prioritizing AI-specific failure modes ^[16]. Applied to an AI document generation system, the risk assessment should address: hallucination of factual content; incorrect citation mapping to source documents; omission of safety-relevant information; inconsistent terminology across document sections; inappropriate extrapolation beyond available source data; and performance changes following model updates. Each failure mode should be rated for its potential impact on patient safety or data reliability, with validation controls proportionate to that rating.

To illustrate the risk range: a lower-risk use case might be an AI tool that generates CSR narrative from pre-verified, sponsor-reviewed data tables, where the AI performs templated text production from locked inputs. A higher-risk use case is an AI tool that drafts protocol eligibility criteria from an investigator brochure, where the AI's output directly influences patient selection and safety exposure. The latter warrants stricter validation scope, tighter acceptance criteria, and more intensive human expert review.

Core Validation Documentation

A validation program for an AI document generation tool operating in a GxP context should typically include the following elements:

Validation Deliverables

The URS should define specifically what "validated" means for this tool: which document types are in scope, what source data inputs are acceptable, how citation behavior is specified, what the output format requirements are, and where human review integrates into the workflow. Acceptance criteria for testing should be derived from the URS and should include explicit thresholds for citation accuracy and factual grounding, not only formatting and structure.

Audit Trail Requirements Specific to AI

For AI document generation, the audit trail should capture enough information to reconstruct the state of a document at any point in its production history. Where an AI-generated draft constitutes a GxP record under applicable predicate rules and the organization's SOPs, that draft should be retained in its original form. The progression from AI-generated draft to final approved document is part of the record.

The fields below represent what an audit trail specification for AI document generation should typically address:

Representative Audit Trail Fields

The model version at the time of each document's generation should be recoverable from the audit trail. Where AI systems use commercially hosted models, sponsors should verify whether the platform captures model version at the session level or only at system configuration level, since providers may update underlying model weights without advance notice.

Lifecycle Management and Periodic Review

ICH E6(R3)'s lifecycle review expectation ^[3] means validation of an AI document tool should not be treated as a one-time certification event. Any material change to the system warrants either revalidation or a documented impact assessment confirming that existing validation evidence remains adequate. Material changes include: an update to the base model version by the software provider; revisions to fine-tuning datasets; changes to prompt templates affecting output structure or content; and expansion of use to document types or trial phases not covered by the original validation scope.

Change control procedures for AI systems should be defined in the organization's validation SOPs. Vendor contracts for AI document tools should include notification obligations for material model changes; where a provider cannot offer this, the organization should implement monitoring protocols to detect performance change before it reaches production documents.

Regulatory and Documentation Considerations

Beyond the validation package itself, organizations using AI document generation tools in clinical trials should address several additional documentation elements.

A model card or technical disclosure document for each AI tool should describe the model's intended use, training data sources and curation approach, known limitations, and performance benchmarks relevant to the specific document types being generated. This aligns with the Good AI Practice principles' transparency expectations ^[17] and with GMLP Principle 9's requirements for user information ^[11].

Human review SOPs should specify who reviews AI-generated regulatory content, what qualifications the reviewer should hold, what the reviewer is expected to verify before approving a document, and how that approval is recorded. Where Part 11 applies, electronic signature requirements govern how that approval is captured ^[9]. The SOP should also define the threshold at which an AI-generated document is rejected and regenerated rather than manually corrected, and how that decision is documented.

Where AI document generation tools draw on data from connected systems such as CTMS, EDC, or eCTD repositories, those data flows should be validated and documented. The accuracy of AI-generated content depends on the accuracy and completeness of the inputs. A protocol containing AI-generated text derived from an incorrectly extracted source record is not accurate because the generation step was technically valid.

AI and Automation Perspective

Three AI-specific failure modes warrant detailed attention because none of them surfaces reliably in conventional system validation testing.

How Kitsa Fits Into This Problem

KScribe, Kitsa's regulatory document generation platform, addresses the document types where AI traceability and review requirements are highest: clinical trial protocols, ICFs, IBs, DSURs, and CSRs. Kitsa states that KScribe generates documents with inline citations linking generated content to source passages, providing the attribution record that supports both human reviewer verification and audit trail reconstruction. Kitsa also states that its infrastructure is certified across SOC 2, HIPAA, ISO 27001, and AWS VPC. For regulatory affairs teams building validation packages for AI document tools, or assessing vendor systems against ICH E6(R3) and Part 11 expectations, more information is available at kitsa.ai/regulatory-document-generation.

Key Takeaways

• •ICH E6(R3), endorsed January 6, 2025 (EMA adoption July 23, 2025), requires computerized systems validation as a lifecycle activity, including periodic review to confirm AI tools remain in a validated state after model updates and use-case expansions.
• •The EMA's September 2024 Reflection Paper places responsibility for AI tool fitness-for-purpose on clinical trial sponsors; a vendor's validation attestations do not substitute for sponsor-owned qualification and oversight.
• •FDA's January 2025 draft guidance on AI supporting regulatory decision-making explicitly excludes operational document drafting from its credibility framework scope when outputs do not affect safety, quality, or study reliability. GxP validation expectations under Part 11 and ICH E6(R3) apply where predicate rules and regulated records are involved, independently of this guidance.
• •"High regulatory impact" under the EMA's Reflection Paper and "high-risk AI system" under the EU AI Act are different classifications. AI document drafting tools are not automatically high-risk under the Act's Annex III; a formal organizational classification assessment is needed.
• •Following the EU AI Act's AI Omnibus political agreement (May 7, 2026, pending formal adoption) ^[18], high-risk Annex III obligations are deferred to December 2, 2027, and product-embedded Annex I obligations to August 2, 2028.
• •The January 2026 FDA/EMA Good AI Practice principles provide a shared non-binding framework covering context of use, lifecycle management, human oversight, data governance, and transparency. These are the most current joint signals of where both agencies expect AI governance to develop.
• •Published research found general-purpose LLMs achieving only 57% to 82% factual accuracy in ICF generation without structured human review. Citation accuracy testing should generally be treated as a core acceptance criterion in regulated document-generation validation programs.
• •RAG architectures improve explainability and reviewer efficiency but do not substitute for audit trail and validation compliance under Part 11 or ICH E6(R3).

FAQ

References

Related Articles